AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Incyte enters licensing agreement for a phase II HIV drug.
2003 OCT 8 - (NewsRx.com & NewsRx.net) -- Incyte Corp. (INCY) and Pharmasset, Ltd., announced that they have entered into a collaborative licensing agreement to develop and commercialize the antiretroviral drug Reverset, also known as RVT, D-D4FC, or DPC-817, which is currently in phase IIa clinical development for the treatment of human immunodeficiency virus (HIV) infections under an approved U.S. Food and Drug Administration investigational new drug (IND) application.
Incyte will pay Pharmasset an upfront payment as well as performance milestone payments and future royalties on net sales in exchange for exclusive rights in the U.S., Europe, and certain other markets to develop, manufacture, and market the drug. Pharmasset will retain marketing and commercialization rights in certain territories, including South America, Mexico, Africa, the Middle East, Korea, and China.
Reverset is an oral, once-a-day nucleoside analog that targets the HIV-1 and HIV-2 reverse transcriptase. Preclinical studies indicate that Reverset inhibits replication of wild type and mutant strains of HIV commonly seen after treatment with zidovudine (ZDV) and lamivudine (3TC), including strains that exhibit the M184V mutation. These studies also suggest that Reverset does not produce mitochondrial toxicity, a common side effect associated with certain nucleoside reverse transcriptase inhibitor (NRTI) therapies that can lead to fairly serious and life-threatening bone marrow ...
- Reverset effective when HIV regimens fail.(Infectious Diseases)
- Magazine article from: Internal Medicine News Laino, Charlene September 15, 2005 700+ words
...transcriptase inhibitor Reverset is poised to become the...reporting its promise for HIV-infected patients for...Society Conference on HIV Pathogenesis and Treatment. Reverset was effective in patients with HIV resistant to other commonly...
- Incyte Corporation Conference Call to Discuss Clinical Results From a Phase II...
- News wire article from: The America's Intelligence Wire February 12, 2004 700+ words
...the therapeutic potential of Reverset as a new treatment for HIV patients and whether Reverset will provide an alternative to...which is the actual structure. Reverset is a cytidine analogue inhibitor of HIV RT, which makes it a nucleoside...
- Incyte Corporation Conference Call to Discuss Clinical Results From a Phase II...
- News wire article from: Fair Disclosure Wire February 12, 2004 700+ words
...the therapeutic potential of Reverset as a new treatment for HIV patients and whether Reverset will provide an alternative to...which is the actual structure. Reverset is a cytidine analogue inhibitor of HIV RT, which makes it a nucleoside...
- Event Brief of Incyte Corporation Conference Call to Discuss Clinical Results...
- News wire article from: Fair Disclosure Wire February 12, 2004 700+ words
...Phase II study of Reverset, a citidyne analog inhibitor of HIV RT, which is...Background Data: 1. Reverset is a citidyne analog inhibitor of HIV RT. 1. Nucleoside...saw some anti-HIV activity, with...decrease. 6. Reverset has very high...
- Incyte and Pharmasset Announce Preliminary Findings from Phase II Study of...
- Press release article from: Business Wire February 7, 2004 700+ words
...major scientific meeting. Reverset is currently in Phase...trials for the treatment of HIV infections under an approved...molecule drugs to treat HIV, inflammation, cancer...advanced product candidate, Reverset, is an oral, once...to treat patients with HIV infections. Currently...
- Incyte to Host Conference Call to Discuss Clinical Results From a Phase II...
- Press release article from: Business Wire February 11, 2004 700+ words
...from a Phase II study of Reverset(TM) in treatment...immunodeficiency virus (HIV)-infected patients...call is as follows: -- Reverset Conference Call: 8...molecule drugs to treat HIV, inflammation, cancer...advanced product candidate, Reverset, is an oral, once...
- Incyte and Pharmasset announce preliminary findings from Phase II study of...
- News wire article from: Asia Africa Intelligence Wire February 7, 2004 700+ words
...viral effects and safety of Reverset demonstrated a significant...immunodeficiency virus (HIV). The mean reduction in...77 log10 copies/ml. Reverset is currently in Phase II...trials for the treatment of HIV infections under an approved...
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral...
- Press release article from: Business Wire October 31, 2004 700+ words
...treatment-experienced HIV patients who will be treated with Reverset in combination with...four of the eight Reverset-treated patients had HIV containing three...in patients when HIV becomes resistant...used NRTI drugs." Reverset was well-tolerated...
- Incyte Corporation Conference Call to Discuss Clinical Results From a Phase II...
- News wire article from: The America's Intelligence Wire February 12, 2004 700+ words
...same thing. The major metabolite of Reverset is 5FC and we looked in a very rare metabolite...with them. And this group when you give Reverset 96% of it is going to show up in human...excreted. In the urine you see 92% Reverset, 6% 5FC and 1% 5FU. MICHAEL KING...
- Results of Phase IIa study show that Reverset has potential to reduce HIV viral...
- News wire article from: Asia Africa Intelligence Wire October 31, 2004 700+ words
...group suggest that Reverset may be an effective therapeutic...patients infected with HIV containing specific viral...following treatment with Reverset. Additionally, four of the eight Reverset-treated patients had HIV containing three or more...
Source: HighBeam Research, Incyte enters licensing agreement for a phase II HIV drug.